Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment ; volume:22 ; number:1 ; day:22 ; month:4 ; year:2024 ; pages:1-11 ; date:12.2024
Journal of translational medicine ; 22, Heft 1 (22.4.2024), 1-11, 12.2024
- Creator
-
Ottaiano, Alessandro
Santorsola, Mariachiara
Ianniello, Monica
Ceccarelli, Anna
Casillo, Marika
Sabbatino, Francesco
Petrillo, Nadia
Cascella, Marco
Caraglia, Francesco
Picone, Carmine
Perri, Francesco
Sirica, Roberto
Zappavigna, Silvia
Nasti, Guglielmo
Savarese, Giovanni
Caraglia, Michele
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-024-05184-w
- URN
-
urn:nbn:de:101:1-2407082116473.449036386786
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ottaiano, Alessandro
- Santorsola, Mariachiara
- Ianniello, Monica
- Ceccarelli, Anna
- Casillo, Marika
- Sabbatino, Francesco
- Petrillo, Nadia
- Cascella, Marco
- Caraglia, Francesco
- Picone, Carmine
- Perri, Francesco
- Sirica, Roberto
- Zappavigna, Silvia
- Nasti, Guglielmo
- Savarese, Giovanni
- Caraglia, Michele
- SpringerLink (Online service)
Other Objects (12)
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
TAS
TAS
TAS
TAS
:TAS!
TAS
TAS
TAS
TAS
!"TAS*"
Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
TAS
TAS
TAS
TAS
:TAS!
TAS
TAS
TAS
TAS
!"TAS*"
Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
TAS
TAS
TAS
TAS
:TAS!
TAS
TAS
TAS
TAS
!"TAS*"